DBV Technologies (NASDAQ:DBVT) Releases Quarterly Earnings Results

DBV Technologies (NASDAQ:DBVT) posted its earnings results on Friday. The company reported ($1.10) earnings per share for the quarter, Zacks reports. DBV Technologies had a negative return on equity of 106.07% and a negative net margin of 815.73%.

DBV Technologies Price Performance

NASDAQ DBVT traded up $0.13 on Friday, hitting $7.32. 39,437 shares of the company’s stock were exchanged, compared to its average volume of 178,163. The firm’s 50-day moving average price is $5.05 and its two-hundred day moving average price is $4.11. The firm has a market cap of $150.57 million, a price-to-earnings ratio of -1.63 and a beta of -0.08. DBV Technologies has a fifty-two week low of $2.20 and a fifty-two week high of $8.50.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. StockNews.com began coverage on shares of DBV Technologies in a research report on Monday. They set a “hold” rating for the company. JMP Securities reaffirmed a “market outperform” rating and issued a $10.00 price target on shares of DBV Technologies in a research note on Friday, January 10th.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.